We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

118 hedge funds and large institutions have $163M invested in Rigel Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 39 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,988% more call options, than puts

Call options by funds: $1.02M | Put options by funds: $25K

8% more capital invested

Capital invested by funds: $150M → $163M (+$12.7M)

5% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 39

1.11% less ownership

Funds ownership: 7.4% → 6.29% (-1.1%)

14% less funds holding

Funds holding: 138 → 118 (-20)

61% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 33

Holders
118
Holders Change
-20
Holders Change %
-14.49%
% of All Funds
1.9%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
37
Reduced
39
Closed
33
Calls
$1.02M
Puts
$25K
Net Calls
+$997K
Net Calls Change
+$583K

Top Buyers

1
AC
Armistice Capital
New York
+$12.4M
2
DZ Bank
DZ Bank
Germany
+$1.34M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.25M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.24M
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$525K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.05M
2
Invesco
Invesco
Georgia
-$4.58M
3
Millennium Management
Millennium Management
New York
-$3.68M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$3.03M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$1.2M -$465K -50,673 -39%
Morgan Stanley
27
Morgan Stanley
New York
$907K -$273K -29,764 -33%
Connor, Clark & Lunn Investment Management (CC&L)
28
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$859K +$525K +57,279 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$847K -$3.72K -406 -0.7%
Goldman Sachs
30
Goldman Sachs
New York
$609K -$1.85M -201,803 -83%
Los Angeles Capital Management
31
Los Angeles Capital Management
California
$602K +$109K +11,935 +42%
BCM
32
Bridgeway Capital Management
Texas
$488K – – –
TI
33
Telemetry Investments
New York
$484K +$112K +12,250 +61%
AllianceBernstein
34
AllianceBernstein
Tennessee
$465K +$14.4K +1,570 +5%
CSS
35
Cubist Systematic Strategies
Connecticut
$409K +$94.2K +10,277 +61%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$367K +$138K +15,037 +161%
Prudential Financial
37
Prudential Financial
New Jersey
$360K +$46.2K +5,040 +27%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$327K +$4.83K +527 +2%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$301K +$75K +8,182 +69%
NSEDCP
40
NJ State Employees Deferred Compensation Plan
New Jersey
$300K – – –
Bank of America
41
Bank of America
North Carolina
$277K -$108K -11,748 -39%
HF
42
HRT Financial
New York
$272K -$827K -90,228 -83%
JP Morgan Chase
43
JP Morgan Chase
New York
$258K +$39.1K +4,269 +33%
Invesco
44
Invesco
Georgia
$254K -$4.58M -499,891 -97%
SO
45
STRS Ohio
Ohio
$244K – – –
HSA
46
Hussman Strategic Advisors
Maryland
$234K – – –
Russell Investments Group
47
Russell Investments Group
United Kingdom
$234K +$5.7K +622 +4%
WMSA
48
Weiss Multi-Strategy Advisers
New York
$224K -$41.6K -4,539 -23%
Principal Financial Group
49
Principal Financial Group
Iowa
$199K +$80.3K +8,763 +195%
Man Group
50
Man Group
United Kingdom
$195K +$95.9K +10,465 +411%
1
2
3 4 5

RIGL Hedge Fund Activity: Q4 2022 in Review

118 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2022, worth a combined $163M — up 8.5% from $150M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of RIGL and 13 opened new positions — a net loss of 20 holders — while 39 trimmed existing stakes and 37 added.

The largest buyer was Armistice Capital, adding an estimated $12.4M. The largest seller was Fidelity Investments, cutting an estimated $6.05M.

  • 118 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2022, down from 138 in Q3 2022.
  • Funds reported $163M of Rigel Pharmaceuticals stock for Q4 2022, up 8.5% quarter-over-quarter.
  • 13 funds opened new Rigel Pharmaceuticals positions in Q4 2022 and 33 closed out, a net change of -20 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2022 was Armistice Capital, an estimated $12.4M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2022 was Fidelity Investments, an estimated $6.05M sold.

Based on aggregated 13F filings for Q4 2022.